Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

People who experience migraine in middle age may develop movement disorders later in life

A new study suggests that people who experience migraine in middle age may be more likely to develop Parkinson's disease, or other movement disorders later in life. Those who have migraine with aura may be at double the risk of developing Parkinson's, according to the study published in the September 17, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

18 Sep 2014

Migraine in middle age linked to Parkinson's disease

A paper recently published in American Academy of Neurology suggests that migraine in middle age may indicate an increased risk of developing a movement disorder, such as Parkinson’s disease. The study also showed that people who experienced migraine with aura were twice as likely to develop Parkinson’s disease compared with those who did not suffer from headaches.

18 Sep 2014

Vercise DBS System receives CE Mark approval for treatment of essential tremor

Boston Scientific Corporation has received CE Mark for the Vercise Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET).

17 Sep 2014

Researchers gain new knowledge about complex processes that cause Parkinson's disease

Using advanced computer models, neuroscience researchers at the University of Copenhagen have gained new knowledge about the complex processes that cause Parkinson's disease. The findings have recently been published in the prestigious Journal of Neuroscience.

17 Sep 2014

Six research institutions awarded NIH grants to create database of human cellular responses

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures.

15 Sep 2014

New class of compounds protect brain cells from traumatic brain injury

A new class of compounds has now been shown to protect brain cells from the type of damage caused by blast-mediated traumatic brain injury (TBI).

12 Sep 2014

Research gives scientists new insight into evolution of gibbon genome

A team led by an Oregon Health & Science University researcher has sequenced and annotated the genome of the only ape whose DNA had yet to be sequenced - the gibbon, an endangered small ape that inhabits the tropical forests of Southeast Asia.

11 Sep 2014

Study looks at blood type and risk of cognitive impairment

People with blood type AB may be more likely to develop memory loss in later years than people with other blood types, according to a study published in the September 10, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

11 Sep 2014

Pollution in many cities threatens brain development in children

Pollution in many cities threatens the brain development in children. Findings by University of Montana Professor Dr. Lilian Calder-n-Garcidue-as, MA, MD, Ph.D., and her team of researchers reveal that children living in megacities are at increased risk for brain inflammation and neurodegenerative changes, including Alzheimer's or Parkinson's disease.

11 Sep 2014

AMPK gene can slow aging process when activated remotely in key organ systems

UCLA biologists have identified a gene that can slow the aging process throughout the entire body when activated remotely in key organ systems.

9 Sep 2014

Research to help patients suffering from severe spinal cord injuries

Many patients suffer from severe spinal cord injuries after being involved in traffic accidents or accidents at work.

5 Sep 2014

Researchers examine link between sleep difficulties and brain volume

Sleep difficulties may be linked to faster rates of decline in brain volume, according to a study published in the September 3, 2014, online issue of Neurology-, the medical journal of the American Academy of Neurology.

4 Sep 2014

Using iPS technology researchers develop new therapies for Parkinson's disease and ALS

Dresden. Dr. Jared Sterneckert is entering the research area "Neurodegenerative Diseases" of the DFG Research Center and Cluster of Excellence at the TU Dresden as a new junior group leader. Since 2006, he has led a team working at the "Max Planck Institute for Molecular Biomedicine" in Münster to develop models of Parkinson's disease and amyotrophic lateral sclerosis.

3 Sep 2014

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

HSP90 suggested as potential therapeutic target in PD

Heat shock protein (HSP90) has been suggested to be involved in neuronal protein misfolding and accumulation in Parkinson's disease (PD) brains leading to dopaminergic neuronal death and the eventual dopamine depletion.

28 Aug 2014

Researchers find roving detection system for treating cancer, Parkinson's disease and ALS

Duke University researchers have found a "roving detection system" on the surface of cells that may point to new ways of treating diseases like cancer, Parkinson's disease and amyotrophic lateral sclerosis (ALS).

26 Aug 2014

Implantating DBS devices poses no greater risk of complications to older Parkinson's patients

Implantating deep brain stimulation devices poses no greater risk of complications to older patients than it does to younger patients with Parkinson's disease, researchers at Duke Medicine report.

26 Aug 2014

Study sheds new light on sleep drunkenness disorder

A study is shining new light on a sleep disorder called "sleep drunkenness". The disorder may be as prevalent as affecting one in every seven people. The research is published in the August 26, 2014, print issue of Neurology, the medical journal of the American Academy of Neurology.

26 Aug 2014

Actavis files ANDA for generic version of Neupro

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.

25 Aug 2014

Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved doses and/or for long periods of time, these prescription-level NSAIDs and other drugs that affect the membrane may produce wide-ranging and unwanted side effects.

22 Aug 2014